Literature DB >> 19807506

Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin.

B A Craig1, M A Black.   

Abstract

In recent years, an alternative framework for cost-effectiveness analyses has been growing in popularity. Instead of the incremental cost-effectiveness ratio for which statistical inference is often difficult, the incremental net-health benefit (INHB), a linear transformation of incremental costs and effectiveness, has been utilized. The linear structure of this statistic allows easy computation and interpretation of confidence intervals, hypothesis tests and acceptability curves. It is often difficult, however, to switch decision-making procedures without first verifying the appropriateness of the new methods. In this paper, we demonstrate the decision-making similarities between the INHB and the incremental cost-effectiveness ratio and describe how the INHB can be used to clarify inference of the incremental cost-effectiveness ratio. We also describe the two statistics in terms of the DeltaE-DeltaC plane, thus allowing both a mathematical and graphical comparison of these similarities. We conclude with a general discussion of cost-effectiveness analyses and advocate Bayesian, rather than frequentist inference as the more intuitive and powerful decision-making framework.

Year:  2001        PMID: 19807506     DOI: 10.1586/14737167.1.1.37

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  13 in total

1.  Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China.

Authors:  Xiaoyu Yan; Xiaohua Gu; Lei Zhou; Houweng Lin; Bin Wu
Journal:  Clin Drug Investig       Date:  2016-12       Impact factor: 2.859

2.  The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.

Authors:  Bin Wu; Shun Lu
Journal:  Transl Lung Cancer Res       Date:  2020-10

3.  Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.

Authors:  Xiaoyu Yan; Xiaohua Gu; Zhenxing Xu; Houweng Lin; Bin Wu
Journal:  Adv Ther       Date:  2016-12-20       Impact factor: 3.845

4.  Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China.

Authors:  Xingyun Hou; Xu Wan; Bin Wu
Journal:  Front Pharmacol       Date:  2019-05-08       Impact factor: 5.810

5.  Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.

Authors:  Bin Wu; Fei Ma
Journal:  Ther Adv Med Oncol       Date:  2020-05-05       Impact factor: 8.168

6.  Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer.

Authors:  Xuezhi Hao; Aizong Shen; Bin Wu
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

7.  Benefit-Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project.

Authors:  Kaatje Bollaerts; Tom De Smedt; Katherine Donegan; Lina Titievsky; Vincent Bauchau
Journal:  Drug Saf       Date:  2018-08       Impact factor: 5.606

8.  Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China.

Authors:  Shukui Qin; Eliza Kruger; Seng Chuen Tan; Shuqun Cheng; Nanya Wang; Jun Liang
Journal:  Cost Eff Resour Alloc       Date:  2018-08-04

9.  Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.

Authors:  Ambica Parmar; Tina Jiao; Ronak Saluja; Kelvin K W Chan
Journal:  Cancer Med       Date:  2019-11-11       Impact factor: 4.452

10.  Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise.

Authors:  Hua Nian; Xu Wan; Jing Ma; Fu Jie; Bin Wu
Journal:  Cost Eff Resour Alloc       Date:  2020-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.